+Compare
GTHX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
85.02M

GTHX Price Prediction, G1 Therapeutics AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for GTHX with price predictions
07:00 PM EST Nov 30, 2023

Momentum Indicator for GTHX turns positive, indicating new upward trend

GTHX saw its Momentum Indicator move above the 0 level on November 20, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for GTHX just turned positive on November 14, 2023. Looking at past instances where GTHX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

GTHX moved above its 50-day moving average on November 13, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GTHX crossed bullishly above the 50-day moving average on October 31, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GTHX advanced for three days, in of 264 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 160 cases where GTHX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GTHX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GTHX broke above its upper Bollinger Band on November 30, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.037) is normal, around the industry mean (20.645). P/E Ratio (0.000) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (1.093) is also within normal values, averaging (329.009).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GTHX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GTHX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

GTHX is expected to report earnings to fall 17.83% to -28 cents per share on February 21

G1 Therapeutics GTHX Stock Earnings Reports
Q4'23
Est.
$-0.29
Q3'23
Missed
by $0.01
Q2'23
Beat
by $0.36
Q1'23
Beat
by $0.11
Q4'22
Beat
by $0.08
The last earnings report on November 01 showed earnings per share of -34 cents, missing the estimate of -34 cents. With 1.13M shares outstanding, the current market capitalization sits at 85.02M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 27%. MMIRF experienced the highest price growth at 247%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 184%. For the same stocks of the Industry, the average monthly volume growth was -4% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 62
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of drugs for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
700 Park Offices Drive
Phone
+1 919 213-9835
Employees
170
Web
https://www.g1therapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UURAF0.470.01
+3.09%
Ucore Rare Metals
DTRUY16.430.27
+1.67%
DAIMLER TRUCK HLDG AG American Depositary Receipts - Sponsored
FBMCX11.900.12
+1.02%
Franklin Managed Income C
BKRIY9.400.02
+0.21%
Bank Ireland Group PLC
ATHOF2.83-0.04
-1.26%
Athabasca Oil Corp

GTHX and

Correlation & Price change

A.I.dvisor indicates that over the last year, GTHX has been closely correlated with SRNEQ. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if GTHX jumps, then SRNEQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GTHX
1D Price
Change %
GTHX100%
+6.38%
SRNEQ - GTHX
66%
Closely correlated
-2.49%
MDGL - GTHX
49%
Loosely correlated
+4.83%
GOSS - GTHX
46%
Loosely correlated
+8.16%
CYTK - GTHX
40%
Loosely correlated
+0.27%
ONTX - GTHX
35%
Loosely correlated
+1.51%
More